Overall, these results suggest that low ACAP1 levels are associated with a decreased response rate and worse clinical outcomes in ICT-treated patients, highlighting the potential clinical significance of ACAP1 for identifying patients who will benefit from ICT across multiple cancer types, especially for melanoma and lung cancer patients. This evidence concerns the gene ACAP1 and lung cancer.